Navigation Links
Circadian Commences First Phase 1 Clinical Trial of VEGF-C Antibody VGX-100 in Cancer Patients
Date:1/8/2012

MELBOURNE, Australia, Jan. 8, 2012 /PRNewswire/ -- Circadian Technologies Limited (ASX:CIR, OTCQX:CKDXY) announced today that it has commenced the first Phase 1 clinical trial of its fully human monoclonal antibody against VEGF-C, VGX-100, at a leading US-based cancer treatment centre.

The Phase 1 study will examine the safety and tolerability of escalating doses of VGX-100 in patients with advanced solid tumours who have no other standard treatment options both as a monotherapy and also when used in combination with other anti-angiogenic agents.  Results from the trial are expected to be available in the second half of 2012.

"We are extremely proud to have completed the translation of VGX-100 from early discovery to the clinical development stage. We are committed to improving outcomes for patients suffering from cancer, and believe that VGX-100, especially when combined with existing therapies could make a significant difference. Commencing clinical trials with VGX-100 is an extremely important achievement for Circadian and a major step in our goal to develop VGX-100 as a new therapeutic agent in the fight against cancer," said Robert Klupacs, CEO of Circadian Technologies Limited.

VGX-100 is a human antibody that acts against the human VEGF-C protein.  Treatment for cancers, particularly glioblastoma and metastatic colorectal cancers, are the first target indications for VGX-100. Additionally, Circadian is developing VGX-100 for a number of other cancer indications, as well as an agent to treat front-of the-eye diseases.

Studies in animal model studies across a wide range of tumour types have shown that when combined with Avastin® and/or chemotherapy, VGX-100 can significantly reduce tumour growth and tumour spread as well as significantly improve tumour inhibition over and above that of Avastin® and/or chemotherapy alone. Recent studies have also implicated VEGF-C as a key mediator of disease
'/>"/>

SOURCE Circadian Technologies Limited
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Circadiance Launches Revolutionary New CPAP Tube
2. Circadian Receives FDA IND Approval to Begin Clinical Trials With VGX-100 for the Treatment of Cancer Patients With Solid Tumors
3. Circadian Files IND With FDA for VGX-100 for the Treatment of Cancer Patients With Solid Tumors
4. Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet
5. Ikaria® Commences Global Registration Trial for Bioabsorbable Cardiac Matrix
6. Coronado Biosciences Commences Public Trading on the OTC Bulletin Board
7. Hotspur Technologies Commences US Launch at Veith/AIM Conference in New York City
8. CryoLife Commences Tender Offer for All Outstanding Shares of Cardiogenesis Corporation
9. Unilife Commences Initial Production of Unifill Prefilled Syringe
10. Quest Diagnostics Commences Tender Offer for Acquisition of Celera
11. Milestone Scientific Inc. Commences Trading on the OTC Pink
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... 11, 2014 According to a ... Devices Market (Endoscopes, Endoscopic Operative Devices, and Visualization Systems) ... Forecast, 2013-2019" the global endoscopy devices market was valued ... to grow at a CAGR of 6.8% from 2013 ... 36.9 billion in 2019. Browse the full ...
(Date:7/10/2014)... 11, 2014  Major advances in radiation therapy ... being highlighted in a three-day Oncology Summit taking ... July, 2014.  Renowned national and international cancer experts from ... and exchange knowledge on modern technologies making treatment ... The Summit will address a ...
(Date:7/10/2014)... SAN DIEGO , July 10, 2014  RESMED INC. ... report its fourth quarter and fiscal year ended June 30, ... York Stock Exchange market close. A press release with ResMed,s ... and the company will host a webcast to discuss operating ... scheduled to begin at 1:30 p.m. US Pacific Time and ...
Breaking Medicine Technology:Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 2Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 3Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 4Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 5Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 6Improving quality and access to advanced cancer care in India and South Asia 2Improving quality and access to advanced cancer care in India and South Asia 3Improving quality and access to advanced cancer care in India and South Asia 4Improving quality and access to advanced cancer care in India and South Asia 5ResMed To Announce Fourth Quarter And Fiscal Year-End 2014 Results 2
... , , STAMFORD, Conn. , Feb. ... subsidiary of Speedus Corp. (Nasdaq: SPDE ), was jointly named ... February 11th—the 163rd birthday of renowned inventor Thomas Alva Edison—at a ... City . Edison created many of the products and technologies taken ...
... , , REDWOOD CITY, Calif. , Feb. ... collaborations in pharmaceutical manufacturing with Dishman Pharmaceuticals and Chemicals ... American Pacific Corporation. These agreements expand the application of ... pharmaceutical products. , Under the new agreements, Codexis ...
Cached Medicine Technology:Zargis Cardioscan Jointly Named as Finalist in 2010 Edison Best New Product Awards 2Zargis Cardioscan Jointly Named as Finalist in 2010 Edison Best New Product Awards 3Codexis Expands Pharmaceutical Manufacturing Partnerships 2Codexis Expands Pharmaceutical Manufacturing Partnerships 3
(Date:7/12/2014)... Pittsburgh, PA (PRWEB) July 12, 2014 "The ... so it’s uncomfortable and painful to wear shoes," said an ... a special sock that prevents this from happening. , He ... an effective way to prevent the second and big toes ... more endurance while wearing shoes. Ergonomic and easy to use, ...
(Date:7/12/2014)... “After my mom’s stroke, she loss the use of ... the use of his left side. Eating became a difficult task ... people like them enjoy eating again,” said an inventor, from Fayetteville, ... CAROL HALL PLATE (P C H PLATE). , The PATRICIA CAROL ... to eat for individuals who suffer from stroke, experience tremors or ...
(Date:7/12/2014)... New York, New York (PRWEB) July 12, 2014 ... ) continue to move forward in U.S. courts, Bernstein ... that ties elevated metal ion levels to the failure ... the July 2nd issue of The Journal of Bone ... had received unilateral Articular Surface Replacement prostheses at ...
(Date:7/12/2014)... Beverly Hills, CA (PRWEB) July 12, 2014 ... reason why are bodies can readily absorb the nutrients in ... into tiny particles that are small enough to be absorbed ... the DZ10 team, a lack of enzymes in regular food ... DZ10 is a product that was started by Michelle DelPresto, ...
(Date:7/12/2014)... Albany, NY (PRWEB) July 12, 2014 ... to 2020 - New and Late-Stage Four-Factor PCCs ... in-depth analysis of the critical care market in ... and Canada. The report provides an estimation of ... to 2020. It covers critical care indications that ...
Breaking Medicine News(10 mins):Health News:DePuy Pinnacle Hip Lawsuit News: Bernstein Liebhard LLP Notes Release of New Study Tying Elevated Metal Ions to Metal-on-Metal Hip Failure 2Health News:DePuy Pinnacle Hip Lawsuit News: Bernstein Liebhard LLP Notes Release of New Study Tying Elevated Metal Ions to Metal-on-Metal Hip Failure 3Health News:DePuy Pinnacle Hip Lawsuit News: Bernstein Liebhard LLP Notes Release of New Study Tying Elevated Metal Ions to Metal-on-Metal Hip Failure 4Health News:New Super Digestive Enzyme, DZ10, Supercharges The Digestion Process 2Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 2Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 3Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 4Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 5Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 6
... French . , Recent animal studies have ... used to treat diarrhea and other gastrointestinal disorders ... diseases. Scientists, however, had a variety of theories to ... such similar effects on three unrelated neurodegenerative disorders. , ...
... AMERIGROUP Corporation (NYSE: AGP ) today announced that ... Conference on January 14 in San Francisco.A live broadcast of ... p.m. Eastern Time, can be accessed on AMERIGROUP,s Web site, ... be available for 30 days, and can be accessed at ...
... Jan. 6, Halo Pharmaceutical, Inc., a privately ... completion of its acquisition of the Whippany-NJ Manufacturing ... ABT ). At over 200,000 square feet, ... including an impressive array of formulation services, operations ...
... remain stableWASHINGTON, Jan. 6 Karen Ignagni, President and CEO ... data released by CMS today showing that health spending in ... decade at 6.1 percent in 2007. According to the ... 2007, the same rate as in 2006, but much lower ...
... UCSF has received a $7.5 million grant from the Bill & ... to help address Africa,s urgent need for healthcare workers. , ... ... San Francisco has received a $7.5 million grant from the Bill ...
... With 30 million drivers in the US aged 65 ... they can no longer drive safely and decide that it,s ... that a decrease in vision function is a key factor ... and Driving Study (SEEDS) ( http://www.iovs.org/cgi/content/full/50/1/107 ), conducted by researchers ...
Cached Medicine News:Health News:Old gastrointestinal drug slows aging, McGill researchers say 2Health News:Halo Pharmaceutical, Inc. Acquires Whippany Manufacturing Facility from Abbott 2Health News:Halo Pharmaceutical, Inc. Acquires Whippany Manufacturing Facility from Abbott 3Health News:AHIP Statement on National Health Expenditure Data 2Health News:UCSF and Muhimbili University Launch Initiative to Strengthen Tanzanian Health Workforce 2Health News:UCSF and Muhimbili University Launch Initiative to Strengthen Tanzanian Health Workforce 3Health News:Vision problems prompt older drivers to put down the keys 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: